Fluke Hall, Suite 300, Box 352141
4000 Mason Road
About Pascal BiosciencesPascal Biosciences Inc. (formerly, bioMmune Technologies Inc.) is a biopharmaceutical company engaged in the exciting new field of immunotherapy, the discovery and development of new therapeutics that enable the body’s own immune system to recognize and attack infections, cancers and autoimmune diseases.
CEO: Patrick W. Gray
CFO: Judi Dalling
19 articles about Pascal Biosciences
Rob Gietl Joins Pascal Biosciences as New Chief Executive Officer
Pascal Biosciences Inc. announced today the appointment of Rob Gietl as Chief Executive Officer and President, and he will also have a position on the Board of Directors.
Hardy Forzley Joins Pascal Biosciences as Chief Financial Officer
Pascal Biosciences Inc., announced the appointment of Hardy Forzley as Chief Financial Officer.
Pascal Biosciences Awarded NIH Grant For Leukemia Program
Pascal Biosciences Inc., has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health.
Pascal Biosciences Announces New OTC Markets Trading Symbol PSCBF
Pascal Biosciences Inc., has received a new Over The Counter trading symbol following acceptance of Form 211 by the US Financial Industry Regulatory Authority.
Pascal Biosciences Announces Management Changes
Pascal Biosciences Inc. is announcing several management changes following its recent capital raise. First, Chairman of the Board Karoly Nikolich is stepping down from the Board of Directors.
Enosi Life Sciences Appoints Drug Discovery Veteran Patrick Gray as its Newest Board Member
Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced its appointment of Patrick Gray, CEO of Pascal Biosciences, as its newest board member.
Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
Pascal Biosciences, Inc. (TSXV:PAS)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascals development program for treatment of glioblastoma with PAS-403.
Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications
Pascal Biosciences Inc. announced the appointment of Mark van der Horst to the position of Vice President of Corporate Communications.
Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit
Pascal Biosciences Inc. (TSXV:PAS) oday Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in each of Pascal's three cannabinoid programs. The title of his presentation is "Identifying and Validating Mechanism of Action In Vivo and In Vitro".
Biotech Company Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials
Pascal Biosciences Inc. and SōRSE Technology Corporation have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing.
Pascal Biosciences and SōRSE Technology Announce Partnership for Cannabinoid Drug Development and Cancer Clinical Trials
Pascal Biosciences Inc. (TSXV:PAS) ("Pascal") and SōRSE Technology Corporation ("SōRSE") have entered into a Collaborative Research Agreement (the "Agreement") to advance Pascal's PAS-393 into clinical testing.
Pascal Biosciences Announces Listing on the Frankfurt Stock Exchange
Pascal Biosciences Inc. is pleased to announce that its common shares were accepted for listing on the Frankfurt Stock Exchange under the trading symbol | ISIN: CA7024781089 | WKN: A2DQU4.
Pascal Biosciences Announces Feature Article
Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") is pleased to announce it has been featured in an article published by Kathy Woudzia regarding the Company's patent-pending discovery of cannabinoid treatment for Covid-19
Pascal Biosciences Discovers a Cannabinoid That Combats Coronavirus
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 14, 2020 / Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") today announced the Company has discovered certain cannabinoids that block replication of SARS-CoV-2, the coronavirus that causes COVID-19. In a cell-based assay, the best cannabinoid had potency similar to remdesivir, a recently approved drug from Gilead that improves recovery time for COVID-19 patients. This suggests a Pascal-identifie
Pascal Biosciences Appoints Dr. Michael Shepard to Board of Directors
Pascal Biosciences Inc. (TSXV:PAS)(OTC PINK:BIMUF) ("Pascal" or the "Company") today announced the appointment of Dr. H. Michael Shepard to its Board of Directors.
SōRSE Technology Partners with & Acquires Part of Cancer Research Group Pascal Biosciences for Cannabinoid Research Programs
Pascal Biosciences Inc. has entered into a Term Sheet with SōRSE Technology to develop Pascal’s cannabinoid programs.
Pascal Biosciences and Y-Biologics Announce Research Collaboration for Development of a Bispecific Antibody for LeukemiaThe project will utilize Pascal’s proprietary antibodies & Y-Biologics’ novel bispecific antibody platform technology, ALiCE
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today announced a research collaboration agreement for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Under the terms of the agreement, Y-Biologics will contribute its novel bispecific antibody platform technology, ALiCE, and Pascal will utilize its proprietary antibodies.
Pascal Biosciences Engages CFN Media to Build New Investor Audience
CFN Media Group announced that Pascal Biosciences, Inc. (TSX-V:PAS) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on June 19, 2018.
Pascal Biosciences Acquires Technology To Treat Leukemia From The University of New Mexico